...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes, obesity & metabolism >Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study
【24h】

Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study

机译：实现LDL胆固醇靶含量<1.81mmol / L可以在高风险患者中提供额外的心血管保护：对高胆固醇血症和糖尿病视网膜病变患者的标准与强烈他汀类药物治疗的探索性分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims To assess the benefits of intensive statin therapy on reducing cardiovascular (CV) events in patients with type 2 diabetes complicated with hyperlipidaemia and retinopathy in a primary prevention setting in Japan. In the intension‐to‐treat population, intensive therapy [targeting LDL cholesterol 1.81 mmol/L (70 mg/dL)] was no more effective than standard therapy [LDL cholesterol ≥2.59 to 3.10 mmol/L (≥100 to 120 mg/dL)]; however, after 3 years, the intergroup difference in LDL cholesterol was only 0.72 mmol/L (27.7 mg/dL), and targeted levels were achieved in 50% of patients. We hypothesized that the intergroup difference in CV events would have been statistically significant if more patients had been successfully treated to target. Materials and Methods This exploratory post hoc analysis focused on intergroup data from patients who achieved their target LDL cholesterol levels. The primary endpoint was the composite incidence of CV events. A Cox proportional hazards model was used to estimate hazard ratios (HRs) for incidence of the primary endpoint in patients who achieved target LDL cholesterol levels in each group. Results Data were analysed from 1909 patients (intensive: 703; standard: 1206) who achieved target LDL cholesterol levels. LDL cholesterol at 36?months was 1.54?±?0.30?mmol/L (59.7?±?11.6?mg/dL) in the intensive group and 2.77?±?0.46 mmol/L (107.1?±?17.8?mg/dL) in the standard group ( P ??0.05). After adjusting for baseline prognostic factors, the composite incidence of CV events or deaths associated with CV events was significantly lower in the intensive than the standard group (HR 0.48; 95% confidence interval 0.28‐0.82; P ?=?0.007). Conclusions This post hoc analysis suggests that achieving LDL cholesterol target levels 1.81?mmol/L may more effectively reduce CV events than achieving target levels ≥2.59 to 3.10 mmol/L in patients with hypercholesterolaemia and diabetic retinopathy.
机译：旨在评估强烈的他汀类药物治疗对2型糖尿病患者的心血管（CV）事件的益处，其在日本的主要预防环境中具有高脂血症和视网膜病变。在内涵到治疗群体中，强化治疗[靶向LDL胆固醇＆ 1.81mmol / L（＆ 70mg / dl）]没有比标准治疗[LDL胆固醇≥2.59至＆ 3.10mmol / l（ ≥100至＆ 120 mg / dl）];然而，3年后，LDL胆固醇的依法差异仅为0.72mmol / L（27.7mg / dl），并且靶向水平均为50％的患者。我们假设如果更多患者已成功处理到目标，则CV事件的帧组差异将是统计学意义的。材料和方法该探索性后HOC分析专注于患者患者患者患者的杂项数据。主要终点是CV事件的复合发生率。 COX比例危害模型用于估算患者患者患者的危险比率（HRS），用于达到每组LDL胆固醇水平的患者。结果数据从1909名患者（密集：703;标准：1206）分析了目标LDL胆固醇水平。 LDL胆固醇在36？几个月的时间为1.54？±0.30？mmol / L（59.7？±11.6×mg / dl）和2.77？±0.46mmol / L（107.1？±17.8？mg / dl ）在标准组（p≤≤0.05）中。在调整基线预后因素后，密集组中与CV事件相关的CV事件或死亡的复合发生率显着降低（HR 0.48; 95％置信区间0.28-0.82; p？= 0.007）。结论这种后HOC分析表明，实现LDL胆固醇靶水平＆ 1.81？mmol / l可以更有效地降低CV事件，而不是在高胆固醇血症和糖尿病视网膜病变患者中实现目标水平≥2.59至3.10mmol / L.

著录项

  • 来源
    《Diabetes, obesity & metabolism》 |2019年第4期|共10页
  • 作者

    Itoh Hiroshi; Komuro Issei; Takeuchi Masahiro; Akasaka Takashi; Daida Hiroyuki; Egashira Yoshiki; Fujita Hideo; Higaki Jitsuo; Hirata Ken‐ichi; Ishibashi Shun; Isshiki Takaaki; Ito Sadayoshi; Kashiwagi Atsunori; Kato Satoshi; Kitagawa Kazuo; Kitakaze Masafumi; Kitazono Takanari; Kurabayashi Masahiko; Miyauchi Katsumi; Murakami Tomoaki; Murohara Toyoaki; Node Koichi; Ogawa Susumu; Saito Yoshihiko; Seino Yoshihiko; Shigeeda Takashi; Shindo Shunya; Sugawara Masahiro; Sugiyama Seigo; Terauchi Yasuo; Tsutsui Hiroyuki; Ueshima Kenji; Utsunomiya Kazunori; Yamagishi Masakazu; Yamazaki Tsutomu; Yo Shoei; Yokote Koutaro; Yoshida Kiyoshi; Yoshimura Michihiro; Yoshimura Nagahisa; Nakao Kazuwa; Nagai Ryozo; for the EMPATHY Investigators;

  • 作者单位

    Department of Endocrinology Metabolism and NephrologyKeio University School of MedicineTokyo Japan;

    Department of Cardiovascular MedicineUniversity of Tokyo Graduate School of MedicineTokyo Japan;

    Department of Clinical Medicine (Biostatistics and Pharmaceutical Medicine)School of Pharmacy;

    Department of Cardiovascular MedicineWakayama Medical UniversityWakayama Japan;

    Department of Cardiovascular MedicineGraduate School of Medicine Juntendo UniversityTokyo Japan;

    Sakura HospitalFukuoka Japan;

    Department of CardiologySaitama Medical Centre Jichi Medical UniversitySaitama Japan;

    Department of Integrated Medicine and InformaticsEhime University Graduate School of MedicineToon;

    Division of Cardiovascular Medicine Department of Internal MedicineKobe University Graduate School;

    Division of Endocrinology and Metabolism Department of Internal MedicineJichi Medical;

    Division of CardiologyCardiovascular Centre Ageo Central General HospitalAgeo Japan;

    Division of Nephrology Endocrinology and Vascular MedicineTohoku University Graduate School of;

    Kusatsu General HospitalKusatsu Japan;

    Department of OphthalmologyUniversity of Tokyo Graduate School of MedicineTokyo Japan;

    Department of NeurologyTokyo Women's Medical University School of MedicineTokyo Japan;

    Division of CardiologyNational Cerebral and Cardiovascular CentreSuita Japan;

    Department of Medicine and Clinical ScienceGraduate School of Medical Sciences Kyushu;

    Department of Medicine and Biological ScienceGunma University Graduate School of MedicineMaebashi;

    Department of CardiologyGraduate School of Medicine Juntendo UniversityTokyo Japan;

    Department of OphthalmologyKyoto University Graduate School of MedicineKyoto Japan;

    Department of CardiologyNagoya University Graduate School of MedicineNagoya Japan;

    Department of Cardiovascular MedicineSaga UniversitySaga Japan;

    Division of Nephrology Endocrinology and Vascular MedicineTohoku University HospitalSendai Japan;

    First Department of Internal MedicineNara Medical UniversityKashihara Japan;

    Department of CardiologyNippon Medical School Chiba Hokusoh HospitalInzai Japan;

    Ideta Eye ClinicKumamoto Japan;

    Department of Cardiovascular SurgeryTokyo Medical University Hachioji Medical CentreHachioji Japan;

    Sugawara Medical ClinicTokyo Japan;

    Department of CardiologyJinnouchi HospitalKumamoto Japan;

    Department of Endocrinology and MetabolismYokohama City University School of MedicineYokohama Japan;

    Department of Cardiovascular MedicineFaculty of Medical Sciences Kyushu UniversityFukuoka Japan;

    Department of EBM ResearchInstitute for Advancement of Clinical and Translational Science Kyoto;

    Division of Diabetes Metabolism and Endocrinology Department of Internal MedicineJikei University;

    Department of Cardiovascular and Internal MedicineKanazawa University Graduate School of;

    Clinical Research Support Centre University of Tokyo HospitalTokyo Japan;

    Yo ClinicKyoto Japan;

    Department of Clinical Cell Biology and MedicineChiba University Graduate School of MedicineChiba;

    Sakakibara Heart Institute of OkayamaOkayama Japan;

    Division of Cardiology Department of Internal MedicineJikei University School of MedicineTokyo;

    Kitano Hospital Tazuke Kofukai Medical Research InstituteOsaka Japan;

    Medical Innovation Centre Kyoto University Graduate School of MedicineKyoto Japan;

    Jichi Medical UniversityShimotsuke Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 内分泌腺疾病及代谢病;
  • 关键词

    cardiovascular disease; clinical trial; diabetic retinopathy; dyslipidaemia; lipid‐lowering therapy;

    机译：心血管疾病;临床试验;糖尿病视网膜病;血脂血症;降脂治疗;

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号